207 related articles for article (PubMed ID: 33650653)
1. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
3. Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma.
Arakawa N; Miyagi E; Nomura A; Morita E; Ino Y; Ohtake N; Miyagi Y; Hirahara F; Hirano H
J Proteome Res; 2013 Oct; 12(10):4340-50. PubMed ID: 23805888
[TBL] [Abstract][Full Text] [Related]
4. Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways.
Xia Y; Ye S; Yang Y; Liu Y; Tong G
Int J Med Sci; 2021; 18(3):785-791. PubMed ID: 33437214
[No Abstract] [Full Text] [Related]
5. Investigating the efficacy of tissue factor pathway inhibitor‑2 as a promising prognostic marker for ovarian cancer.
Maehana T; Kawaguchi R; Nishikawa K; Kawahara N; Yamada Y; Kimura F
Oncol Lett; 2024 Jul; 28(1):302. PubMed ID: 38774455
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
7. HNF-1β in ovarian carcinomas with serous and clear cell change.
DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
[TBL] [Abstract][Full Text] [Related]
8. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
9. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary.
Miyagi E; Arakawa N; Sakamaki K; Yokota NR; Yamanaka T; Yamada Y; Yamaguchi S; Nagao S; Hirashima Y; Kasamatsu Y; Kato H; Mogami T; Miyagi Y; Kobayashi H
Int J Clin Oncol; 2021 Jul; 26(7):1336-1344. PubMed ID: 34009487
[TBL] [Abstract][Full Text] [Related]
10. Expression of podoplanin in ovarian clear cell carcinoma.
Kotarski J; Marzec-Kotarska B; Szumiło J; Klepacz R; Cybulski M; Małgorzata S; Bednarek W
Ginekol Pol; 2011 May; 82(5):350-3. PubMed ID: 21851033
[TBL] [Abstract][Full Text] [Related]
11. Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma.
Hsu IL; Chou CY; Wu YY; Wu JE; Liang CH; Tsai YT; Ke JY; Chen YL; Hsu KF; Hong TM
Oncotarget; 2016 Sep; 7(39):62925-62938. PubMed ID: 26910837
[TBL] [Abstract][Full Text] [Related]
12. Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma.
Mikami M; Tanabe K; Matsuo K; Miyazaki Y; Miyazawa M; Hayashi M; Asai S; Ikeda M; Shida M; Hirasawa T; Kojima N; Sho R; Iijima S
Gynecol Oncol; 2015 Dec; 139(3):520-8. PubMed ID: 26477941
[TBL] [Abstract][Full Text] [Related]
13. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
16. Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma.
Takaya A; Peng WX; Ishino K; Kudo M; Yamamoto T; Wada R; Takeshita T; Naito Z
Int J Oncol; 2015 Apr; 46(4):1573-81. PubMed ID: 25633807
[TBL] [Abstract][Full Text] [Related]
17. The Application Value of HNF-1β Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma.
Huang W; Cheng X; Ji J; Zhang J; Li Q
Int J Gynecol Pathol; 2016 Jan; 35(1):66-71. PubMed ID: 26166716
[TBL] [Abstract][Full Text] [Related]
18. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
20. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Ho CM; Huang CJ; Huang SH; Chang SF; Cheng WF
BMC Cancer; 2015 Oct; 15():789. PubMed ID: 26497956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
